Evoke Pharma is a pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. Co. is focused on developing its primary product, Gimoti (metoclopramide) nasal spray. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide providing delivery by nasal spray administration. Co. is party to a commercial services agreement with Eversana Life Science Services, LLC, or Eversana, pursuant to which Eversana commercializes and distributes Gimoti in the U.S. We show 43 historical shares outstanding datapoints in our EVOK shares outstanding history coverage, used to compute EVOK market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EVOK market cap history over the course of time is important for investors
interested in comparing EVOK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EVOK versus a peer is one thing; comparing
EVOK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EVOK can fluctuate over the course of history.
With this page we aim to empower investors researching EVOK by allowing them to research the EVOK market cap history. |
Free EVOK Email Alerts:
Video: The Importance of Market Cap
